Polivy (polatuzumab vedotin)
pCPA File Number: 
22584
Negotiation Status: 
Concluded with an LOI
Indication(s): 
Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL, previously untreated in adult patients. (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP))
Sponsor/Manufacturer: 
Hoffmann-La Roche Ltd.
CDA-AMC Project Number: 
PC0313-000
pCPA Engagement Letter Issued: 
Negotiation Process Concluded: